Abstract: The invention relates to materials and methods for therapy to inhibit the production of leukotrienes, and therapeutic and prophylactic applications thereof.

Abstract: The invention relates to methods for inducing a pro-asthma/pro-inflammatory like state in a resident tissue cell, comprising contacting the cell with one or more cytokines, e.g., IL-?, TNF? or both. Methods are also disclosed for identifying genes that regulate responses to anti-inflammatory drugs, to methods for drug screening, and to methods for identifying genes that correlate with various pro-asthma/pro-inflammatory disease phenotypes.

Abstract: This invention provides an automated system for the processing of data packets, composed of personal identifiers and personal data, such that the personally identifiable data sent by one party may be considered anonymous once received by a second party. The invention uses secret sharing techniques to facilitate distributed key management of the mapping functions and strong authentication to allow the system to be operated remotely.

Abstract: Methods are disclosed for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile of the sample in the absence and presence of in vitro modulation of the cells with specific cytokines and/or mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarities between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.

Abstract: The present invention is directed to pharmaceutical compositions of 7-(acryloyl)indoles, such as 4,5 -Dichloro-thiophene-2-sulfonic acid [(E)-3-[1-(2,4-dichlorophenylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]-acryloyl]amide (DTSI), having a structure shown below. The invention is also directed to methods of treatment utilizing formulations of the DTSI and processes of preparation of the formulations.

Abstract: A chemical genus of biphenyl heterocycle derivative inhibitors of LTA4H (leukotriene A4 hydrolase) of the formula: is disclosed. In these compounds Q and Z are (CH2)1-10; in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; Het is a 5-7 membered non-aromatic nitrogen heterocycle; and W is acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl, or substituted heterocyclyl, or taken together ZW can be H or —COOalkyl. The compounds are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.

Abstract: The present invention relates to a chemical genus of 3-(triaryl)-2-aminopropanol derivative inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention of inflammatory diseases and disorders.

Abstract: Two chemical genera of pyrazolylphenyl and pyrrolylphenyl derivatives are disclosed. They have the general formula: In these compounds ring (a) is a pyrazole or pyrrole; Q is selected from the group consisting of a direct bond, O, S, SO, SO2, NR1, CH2, CF2, and C(O); HET is a 4-7-membered saturated nitrogenous heterocycle; and taken together ZW is H or Z is (CH2)1-10 in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; and W is hydrogen, acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl or substituted heterocyclyl. The compounds are inhibitors of LTA4H (leukotriene A4 hydrolase). They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.

Abstract: The present invention is directed to methods for diagnosing psychiatric disorders in an individual. The methods described herein are directed to determining the orientation of the Inv8p23 inversion fragment by determining the gene expression of informative genes in the Inv8p23 genomic region.

Abstract: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

Abstract: The present invention involves a process for preparing substituted indoles, such as DTSI involving two sequential cross-coupling reactions.

Abstract: The invention relates to methods for inducing a pro-asthma/pro-inflammatory like state in a resident tissue cell, comprising contacting the cell with one or more cytokines, e.g., IL-1?, TNF? or both. Methods are also disclosed for identifying genes that regulate responses to anti-inflammatory drugs, to methods for drug screening, and to methods for identifying genes that correlate with various pro-asthma/pro-inflammatory disease phenotypes.

Abstract: The present invention relates to the usage pattern, commonly found in many software applications, of defining sets of objects based on object attributes. A specifically designed set definition language for defining sets, called SDL, is described and a software system that implements this language efficiently on top of a standard relational database management system (RDBMS) is presented. The unique features of the SDL language are the implicit constraints that are enforced on the relational data that belong to the objects. Unique to the SDL system is also the logical metadata of dimensions that enables the SDL system to enforce these constraints across relations. The SDL system utilizes several optimization techniques to enable efficient implementation on top of RDBMS. It is also shown how the SDL language and the SQL language can be merged with bidirectional inlining using syntactic gates. Query composition tools are also described that facilitate the creation of SDL expressions.

Abstract: Methods are disclosed for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile of the sample in the absence and presence of in vitro modulation of the cells with specific cytokines and/or mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarities between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.

Abstract: A system for editing the dimension structure associated with a data cube is revealed. The editing may be used to enforce given criteria on the cube. This includes modifying the cube in order to satisfy regulations requiring researchers to protect information about individuals, such as medical, genealogy and genetics records. The inference control methods disclosed therefore enable safe aggregated datasets to be released to researchers. When combined with information theoretic methods, the invention method of editing the dimension structures may be used to express clearly and discover correlations that exist in the dataset. This mining of the data and editing of the dimension structure allows the user of a simple multidimensional cube viewer to visually verify the patterns discovered.

Abstract: The invention relates to improved materials and methods for therapy to inhibit production of leukotrienes, and all therapeutic applications thereof.

Abstract: The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with ?-cyclodextrin in an aqueous complexation medium comprising ?-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with ?-cyclodextrin and its inclusion complexes.

Abstract: The invention discloses methods and apparatus that facilitate efficient querying of tables referencing semistructured data such as digraphs and other domains with complex grouping structure. The invention methods enable meaningful indexing of the tables as well as rewriting of queries with respect to the structures. Dynamic schema extraction using proper coloring algorithms is disclosed that structures the semistructured data in such a way that complex set operations and grouping are replaced with traditional relational joins. This enables a relational database system to harness its entire query optimizing capability when querying tables referencing semistructured data.

Abstract: The invention relates to materials and methods of identifying modulators of N-methyl-D-Aspartate (NMDA) receptor phosphorylation and function, including anti-schizophrenic agents that modulate NMDA receptor function. The methods of the invention utilize animal models of schizophrenia and cell-based assays to identify modulators of NMDA function. The invention further provides anti-schizophrenic agents identified by these methods. The invention relates to methods of treating schizophrenia using the modulators and anti-schizophrenic agents identified by the methods of the invention.

Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.